HOME
SEARCH
RSS FEED
SUBSCRIBE
DNA Methylation Based Non-invasive Blood Diagnostic Assay for Precision Cancer Detection and Classification
Case ID:
TAB-3644
Web Published:
12/6/2022
Description:
This technology includes a panel of 46 genomic loci of DNA methylation (represented by CpG dinucleotides on different chromosomes) with application in blood-based cancer screening. The markers robustly distinguish tumor from normal samples using 8 loci and classify 13 different tumor types. Using 39 loci, inventors were able to discriminate between individual tumor types or peripheral blood. In 4052 tumor samples from 13 tumor types, the true positive rate of classification was 91.4%. The false positive rate was 1.2% from 11 normal tissue types (in 646 samples) and 0% using 2711 normal peripheral blood samples. Furthermore, the 39 loci correctly identify the tumor type with a median rate of > 85%. Computational validation occurred in 8 additional DNA methylation datasets including colon, kidney, lung, liver, pancreas, prostate, and breast.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Direct Link:
https://nih.technologypublisher.com/tech/DNA_Methylation_Based_Non-invasive_B lood_Diagnostic_Assay_for_Precision_Cancer_Detection_and_Classification
Category(s):
Research Materials
Diagnostics
Oncology
Therapeutics
Bookmark this page
Download as PDF
For Information, Contact:
Eggerton Campbell
Licensing And Patenting Manager
NIH Technology Transfer
301-402-1648
eggerton.campbell@nih.gov
Inventors:
Gennady Margolin
Laura Elnitski
Keywords:
assay
Based
Blood
CANCER
CLASSIFICATION
Detection
diagnostic
DNA
Humans
Methylation
NON-INVASIVE
PRECISION
VCXXXX
WBXXXX
WIXXXX
XEXXXX
Home
|
Search
|
RSS
|
Subscribe
© 2024. All Rights Reserved. Powered by
Inteum